Loading…
← CockpitCompetitor Analysis › SHUKRAPHAR.NS Shukra Pharmaceuticals Ltd.Open in the cockpit ↗

Shukra Pharmaceuticals Ltd.SHUKRAPHAR.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Mkt cap
$387M
US dollars, full cap
Free float
11%
of shares outstanding
$/day
$6.32M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+26.0 pp
WACC 9.4%
Hurdle
n/a
no reverse DCF
Close · INR₹82.20
1D-0.1%
1W0.0%
1M+19.8%
3M+97.8%
6Mn/a
YTDn/a
1Yn/a
ATR %4.3%
52w lowhigh3.1% off high

What Shukra Pharmaceuticals does

Employees: 211

Shukra Pharmaceuticals at a glance

Size Shukra Pharmaceuticals (SHUKRAPHAR.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $387M, the 964th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹82.20 on 18 Nov 2026.

Growth Revenue grew 222.3% over the last twelve months (peer median -8.0%); the operating margin is 54.5% (peer median -13.4%).

Valuation It trades at 32.0× enterprise value to sales against a peer median of 4.9× (5th most expensive of 18).

Capital Return on invested capital runs 26.0 points above its cost of capital (9.4% WACC).

Shukra Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹1.13B₹567M₹326M₹746M₹588M
Revenue growth—+74%-56%+27%—
Gross profit₹699M₹306M₹156M₹230M₹66.1M
EBITDA₹657M₹290M₹127M₹195M₹64.6M
Net income₹443M₹220M₹95.8M₹185M₹44.1M
Free cash flown/a-₹120M₹60.6M-₹66.8M-₹15.1M
Capital expendituren/a₹157M₹27.4M₹17.6M₹44.9M
Total debt₹225M₹50.2M₹41.8M₹31.5M₹50.8M

Quarterly statements and history in the cockpit →

Shukra Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Fundamentals: revenue growth against valuation

0%+100%+200%0×200×400×42C300534300452002868219AIRDPBYI0025816535SHUKRAPHAR.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shukra Pharmaceuticals is the large dot.

Shukra Pharmaceuticals competitors and peer comparison

How Shukra Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shukra Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureSHUKRAPHAR.NSPeer medianRank in peer set
1-month return+19.8%-13.1%highest of 20
Distance from 52-week high-3.1%-44.6%highest of 21
Revenue growth (TTM)+222.3%-8.0%highest of 18
Operating margin54.5%-13.4%highest of 19
EV / Sales32.0×4.9×5th most expensive of 18
ROIC minus cost of capital+26.0 pp-7.3 pp3rd highest of 17
EV / EBITDA55.2×n/a—
Net debt / EBITDA0.2×-2.9×2nd most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%2.2×-5.5%+12.2%
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%7.2×n/an/a

Questions

Which companies are Shukra Pharmaceuticals's closest peers?
The cockpit's peer set: iX Biopharma (42C.SI), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Avalo Therapeutics (AVTX), SanBio (4592.T), Anhui Sunhere Pharmaceutical Excipients (300452.SZ), Lifecome Biochemistry (002868.SZ), Heartseed (219A.T), JCR Pharmaceuticals (4552.T).
Is Shukra Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 32.0× against a peer median of 4.9×, 5th most expensive of 18 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.